A61K 38/1735
Mucins
Official title: {Mucins, e.g. human intestinal mucin}
A61K38/1735 (Mucins) appears on 44 US grants and 111 published applications in this corpus.
Search patents in A61K- Granted patents
- 44
- Published applications
- 111
- Assignees
- 47
- Inventors
- 137
- Latest grant
- 5 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 2 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 2 |
| 2007 | 0 | 3 |
| 2008 | 0 | 1 |
| 2009 | 0 | 1 |
| 2010 | 0 | 5 |
| 2011 | 0 | 5 |
| 2012 | 0 | 3 |
| 2013 | 2 | 3 |
| 2014 | 3 | 6 |
| 2015 | 7 | 10 |
| 2016 | 2 | 19 |
| 2017 | 4 | 4 |
| 2018 | 3 | 1 |
| 2019 | 3 | 5 |
| 2020 | 2 | 6 |
| 2021 | 6 | 2 |
| 2022 | 3 | 10 |
| 2023 | 1 | 10 |
| 2024 | 2 | 3 |
| 2025 | 4 | 6 |
| 2026 | 2 | 3 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Composition for use in treatment of allergic diseases5 May 2026US 12,617,837 B2University of Tsukuba
- Compositions derived from gastrointestinal tract mucins17 Feb 2026US 12,550,924 B2Gnubiotics Sciences SA
- Infant formula milk powder rich in milk fat globule membrane protein, phospholipids and oligosaccharides and preparation method therefor7 Oct 2025US 12,433,301 B2Beijing Sanyuan Foods Co., Ltd.
- Egg protein formulations and methods of manufacture thereof12 Aug 2025US 12,383,584 B2Societe des Produits Nestle S. A.
- Microbiome markers and uses thereof5 Aug 2025US 12,378,611 B2Gnubiotics Sciences SA
- Compositions and methods relating to age-related, neurological, and vascular disease conditions20 Aug 2026US 2026/0241037 A1The Board of Trustees of the Leland Stanford Junior University
- Reinforcement of mucus barrier properties5 Mar 2026US 2026/0060999 A1Cirqle Biomedical Contraception Ivs
- Vaccine against pancreatic cancer, and medical use thereof12 Feb 2026US 2026/0041749 A1Yuanben (Zhuhai Hengqin) Biotechnology Co., Ltd.
- Methods and compositions for modifying mucous membranes11 Dec 2025US 2025/0375394 A1
- Glycopeptide mediated t cell immunity and anti-tumor efficacy in cancer23 Oct 2025US 2025/0325589 A1Gnubiotics Sciences SA
Most cited
By later US patents
- Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions75US 10,188,748 B2CureVac AG · 2019
- Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions37US 10,568,972 B2CureVac AG · 2020
- Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions37US 11,135,312 B2CureVac AG · 2021
- Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions11US 11,369,691 B2CureVac AG · 2022
- Use of human cells of myeloid leukaemia origin for expression of antibodies8US 9,051,356 B2Glycotope GmbH · 2015